This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.
Written informed consent.
Male or female, ≥18 years of age.
Inoperable/metastatic cutaneous malignant melanoma
Relapsed or newly diagnosed locally advanced inoperable/metastatic TNBC
Receipt of any oncolytic virus treatment, or administration of a vaccine containing live virus within 4 weeks before Day 1.
Use of significant immunosuppressive medication, including high dose corticosteroid (defined as the equivalent of >10 mg/day prednisone) within 4 weeks before Day 1. Inhaled or topical corticosteroid use is allowed.
Prior or concomitant radiotherapy within 4 weeks before Day 1.
Participation in a study with an investigational drug or device within 4 weeks prior to Day 1.
Valo Therapeutics Oy
Lead sponsor